In Big Shift, 23andMe Will Invent Drugs Using Customer Data

Personal genomics and biotech company 23andMe recently announced that it will begin using its customer genetic database to develop medicines itself. The rationale behind this move is that "it will allow it to capture a much greater proportion of the economic value its genetic database could create". In other words, instead of selling information from their database to companies that will use the information to make and sell medicines, they will just do all of that themselves, and make a lot more money.